Lumiracoxib has no significant effect on ethinylestradiol/levonorgestrel PK or PD parameters

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1008, 2004-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ethinylestradiol/levonorgestrel effective in PMDD

By  

Inpharma, Vol. 1, Iss. 1665, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Low-Dose Ethinylestradiol/Levonorgestrel

By Dando Toni M.   Curran Monique P.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2299-2306

Adis International

Access to resources Recommend Favorite

Ethinylestradiol/levonorgestrel a continuing success

By  

Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Ethinylestradiol/levonorgestrel: continuous comparable to cyclic

By  

Inpharma, Vol. 1, Iss. 1543, 2006-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Health Canada has approved ethinylestradiol/levonorgestrel 0.03mg/0.15mg tablets [Seasonale; Paladin Labs] for contraception.

By  

Inpharma, Vol. 1, Iss. 1596, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite